What is Melanotan I?
Melanotan I is a linear peptide designed to bind to melanocortin receptors, especially MC1R, mimicking the biological activity of α-MSH. Its primary effect is to increase melanin synthesis in the skin, offering a potential non-UV means of pigmentation. It has been clinically evaluated for its protective benefits in patients with EPP, a condition marked by painful phototoxic reactions to sunlight exposure [1]. It has shown promise as a safe and effective research tool in pigmentation and light sensitivity studies.
Melanotan I is also known as afamelanotide. In that form it is, in fact, FDA-approved as SCENESSE, a subcutaneous implant cleared in 2019 to increase pain-free light exposure in adults with EPP.
Molecular Formula and Structure
- Amino Acid Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
- Chemical Formula: C78H111N21O19
Melanotan I Research
Photoprotection in EPP
Melanotan I has been shown to significantly increase pain-free sun exposure time in individuals with erythropoietic protoporphyria. In a randomized clinical trial, patients receiving it subcutaneously experienced enhanced pigmentation and photoprotection, resulting in a marked improvement in quality of life [1].
Synergistic Effects with UV-B
Studies have demonstrated that when Melanotan I is used in conjunction with low-dose UV-B exposure, it accelerates and intensifies pigmentation compared to UV-B alone. This indicates that it may serve as a UV-sparing agent in therapeutic settings or research involving controlled pigmentation [2].
Broader Application in Photosensitivity Disorders
Beyond EPP, it is being investigated for use in other UV-sensitive conditions such as solar urticaria and polymorphic light eruption. Its ability to safely stimulate melanin production suggests it may have broader implications for protecting the skin against photodamage [1].
Safety and Tolerability
Clinical trials have reported that Melanotan I is generally well tolerated. Most adverse events were mild, such as transient nausea or facial flushing. No significant toxicity has been reported at therapeutic research doses, supporting its continued evaluation in pigmentation studies [2].
Reconstitution and dosing
Melanotan I is typically reconstituted with Bacteriostatic water at 10mg per ml. Standard dosing typically starts at 250mcg per day 2-3 days per week. Dosing can titrate up to achieve satisfactory results, followed by maintenance dosing to maintain pigmentation.
For our free Peptide Calculator, CLICK HERE. Research-grade Melanotan I is available from WellnessPeptides.
Referenced Citations
- Afamelanotide. Wikipedia. Available at: https://en.wikipedia.org/wiki/Afamelanotide
- Dorr RT, Dvorakova K, Brooks C, et al. “Effects of a superpotent melanotropic peptide in combination with UV-B light in humans.” J Invest Dermatol. 2004. Available at: https://pubmed.ncbi.nlm.nih.gov/15262693/
Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. THIS PRODUCT IS INTENDED FOR RESEARCH PURPOSES ONLY AND IS NOT INTENDED FOR HUMAN CONSUMPTION.
